Biomedical catalyst 2017 – Round 2 late stage

Across the world we are facing increasing healthcare challenges, both physical and financial. There is a need to provide for a growing, ageing population that has an increasing burden of disease. Healthcare costs are rising. The long-term sustainability of current models of provision is in doubt. The need to provide efficient and effective healthcare has never been more important.

To meet these challenges companies and academics must work together.

Biomedical Catalyst awards fund innovative solutions to healthcare challenges. The aim of the late stage award is to test a well-developed concept and show its effectiveness in a relevant environment. It could do this through:

• initial human proof-of-concept studies
• demonstration of clinical utility and effectiveness
• demonstration of safety and efficacy (including phase I and II clinical trials)
• developing production mechanisms
• prototyping
• market testing
• intellectual property protection

These solutions should be innovative healthcare technologies, products or processes that will help provide one or more of the following:

• disease prevention and proactive management of health and chronic conditions
• earlier and better detection and diagnosis of disease, leading to better patient outcomes
• treatments that either change underlying disease or offer potential cures

The Catalyst will support projects from any sector or discipline, including but not limited to:

• stratified healthcare (both therapy and diagnostic components)
• advanced therapies (cell and gene therapy)
• diagnostics
• digital health
• enabling medical technologies and devices